Hormone Replacement Therapy: Rethinking 4 Long-Standing Misconceptions in Women’s Health

Hormone Replacement Therapy: Rethinking 4 Long-Standing Misconceptions in Women’s Health

By: Alana Leavell, APRN; FNP-C 

For years, many of us were trained to prescribe the lowest dose for the shortest duration when it came to hormone replacement therapy (HRT).

Interpretation of the Women’s Health Initiative study raised concerns about increased cancer risk and a lack of cardiovascular benefit associated with HRT in women, prompting a rapid shift toward prescribing at the lowest dose and shortest duration, and a substantial decline in its use among women.¹

But clinical guidance evolves. Regulatory perspectives shift. And our understanding of women’s health continues to deepen.

Today, many providers are revisiting long-held assumptions about HRT, now better known in females as menopause replacement therapy (MRT). These providers are asking a more nuanced question: are we underutilizing a tool that may improve quality of life for appropriately selected patients?

Below are four misconceptions that still surface in clinical conversations.

Misconception 1: “Hormone therapy broadly causes cancer.”

For decades, the narrative around estrogen and testosterone centered on risk amplification. Patients were counseled conservatively, and understandably so.

But risk is not universal. It is patient-specific.

As  additional analyses and regulatory updates have reframed portions of the discussion, the clinical responsibility has shifted toward individualized assessment.² The more relevant question is not whether hormones are inherently dangerous. It is which patients, at what stage of life, with what risk profile, may benefit from carefully monitored hormone optimization.

Nuance matters. Context matters. Personalization matters.

Misconception 2: “Testosterone therapy in women is the same as anabolic steroid use.”

This remains one of the most persistent misconceptions, even among clinicians.

Therapeutic testosterone replacement is not synonymous with anabolic steroid abuse. Anabolic steroids suppress natural hormone pathways and may create supraphysiologic effects. Testosterone replacement as part of MRT aims to restore declining levels to physiological premenopausal levels.³

The risk of conflating therapeutic replacement with misuse is that it limits productive clinical conversations. When appropriately dosed and monitored, testosterone therapy in women has been associated with improvements in sexual health. ⁴ It may also improve muscle mass, energy, and cognitive clarity. As our understanding of female androgen physiology evolves, so should our research pursuits and clinical framework.

Misconception 3: “MRT is primarily about symptom relief.”

Vasomotor symptoms often dominate the conversation, but limiting MRT to hot flashes and night sweats narrows the clinical lens.

Sex hormones play a physiologic role in multiple systems, including bone metabolism. Emerging research continues to explore how hormonal changes across the lifespan influence bone density and musculoskeletal health, particularly in women with elevated fracture risk.⁵

For patients with a family history of spinal or hip fractures, this broadens the discussion beyond symptom management to include long-term health considerations.

Many women are not simply seeking relief. They are seeking strength, resilience, and support for healthy aging.

When we frame MRT solely as symptom management, we overlook its broader physiologic role in a woman’s overall health trajectory. The conversation must expand beyond “managing menopause” and alleviating discomfort to recognizing hormone therapy as part of a proactive strategy designed to support resilience and potentially support long-term health benefits well beyond the menopausal transition.

Misconception 4: “Avoidance equals safety.”

Choosing not to intervene does not eliminate risk.

For some patients, non-intervention is appropriate. For others, individualized hormone optimization may meaningfully alter long-term outcomes. Thoughtful evaluation, shared decision-making, and ongoing monitoring are all tools that could be used to potentially improve outcomes.

A Clinical Inflection Point

Women are actively seeking more sophisticated conversations about aging, vitality, and long-term health. As providers, we have an opportunity to move beyond outdated narratives and re-examine where hormone therapy fits within comprehensive care.

MRT is not a cure-all. But it is also not the villain it was once portrayed to be. When approached with rigor, personalization, and clinical discipline, it becomes a valuable tool in the pursuit of healthier aging.

If you are evaluating how hormone optimization may fit into your clinical model, we welcome the conversation. Expanding responsibly begins with informed dialogue.